U.S. Senate Committee on Judiciary

11/17/2026 | Press release | Distributed by Public on 11/17/2026 14:00

Durbin Pushes For Medicare To Have More Authority To Negotiate Prescription Drug Costs During Senate Judiciary Committee Hearing

Published: 11.17.2026

Durbin Pushes For Medicare To Have More Authority To Negotiate Prescription Drug Costs During Senate Judiciary Committee Hearing

Durbin also railed against congressional Republicans' cuts to Medicaid, saying "How could this be good for the country, for more and more people to be uninsured?"

WASHINGTON - U.S. Senate Democratic Whip Dick Durbin (D-IL), Ranking Member of the Senate Judiciary Committee, today questioned witnesses during the Senate Judiciary Committee hearing entitled "Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs." During the hearing, Durbin spoke about the benefits of providing the federal government with more authority to negotiate the cost of prescription drug prices as the provisions in the Inflation Reduction Act have allowed Medicare to negotiate directly with Big Pharma, yielding enormous savings for taxpayers while allowing Americans to receive their medications at a lower cost.

Durbin began his questioning by emphasizing that research done at the National Institutes of Health (NIH), a taxpayer-funded medical research center, lays the foundation for nearly all new prescription drugs that enter the market.

"Is it true or not true that 95 percent of the new drugs that are available in America started with federal research at the National Institutes of Health?" Durbin asked, to which the witnesses agreed. "The starting point is: the American people are already paying for the basic research that leads to the drugs which they need to stay healthy, true?"

The witnesses affirmed Durbin's analysis.

Durbin then spoke in favor of the Inflation Reduction Act's provision that allowed Medicare to negotiate the price of 10 of the most commonly used prescription drugs.

"Let's talk about the call that many politicians are making for Medicare for All. Let's take a look at Eliquis under Medicare… Eliquis fell into these Part D drugs, the 10 that were reduced in cost through Medicare [under the authority granted by the Inflation Reduction Act]. Eliquis was originally $521 for a 30-day supply. It's now $231 for a 30-day supply. A pretty dramatic [decrease in] cost because the government said to the maker of Eliquis, 'You're entitled to a profit, but you're charging too much. We won't pay it under Medicare,'" Durbin said.

"Out of the 70 million people who are under Medicare, which some politicians brand as socialism, four million take Eliquis. What has happened to the cost to the federal government of this Part D mandate by the government to reduce the 30-day cost of Eliquis from $521 to $231? The federal taxpayers have saved $10 billion for this blood thinner. That's pretty amazing," Durbin continued.

"So the question in my mind is, why don't we just go ahead and go all the way? Why don't we put everyone under Medicare?" Durbin said.

Durbin posed a question to Mr. Alex Oshmyansky, CEO and co-founder of Mark Cuban Cost Plus Drug Company, about how his company is able to pay less for prescription drugs than the federal government.

"Mr. Oshmyansky, I listened to you explain how Mr. Cuban has been able to give people discounts on drugs just by paying what the drug companies are charging, but the federal government is paying more. Why?" Durbin asked.

Mr. Oshmyansky replied that intermediaries mark up the cost of these medications. He explained that cutting out the middleman and allowing the federal government to negotiate directly with pharmaceutical companies will reduce the cost of these medications.

Durbin then asked the witnesses about their stance on Medicare for All.

"Anybody here opposed to Medicare for All?" Durbin asked the panel at large.

While Professor Neeraj Sood of the USC Schaeffer Institute for Public Policy and Government Service expressed some hesitation, Ms. Merith Basey, CEO of Patients for Affordable Drugs Now, spoke about the necessity of tackling the list price of prescription drugs to achieve Medicare for All.

Durbin then spoke out against pharmacy benefit managers (PBMs), which have grown into powerful intermediaries that have contributed to the rise of prescription drug costs by steering patients toward their affiliated pharmacies and marking up the costs.

"If you read a PBM defense what they're doing, it sounds perfectly reasonable. [They say,] 'We're bringing competition and rebates and cuts and discounts,' and yet, when it's all over, Americans pay four times as much as other people around the world for the same [brand-name] drugs. So the system with PBMs is hardly working to the benefit of the consumers," Durbin said.

Turning to Dr. Karriem Watson, CEO of UI Health Mile Square Health Center in Chicago, Durbin asked about the anticipated impact of congressional Republicans' so-called One Big Beautiful Bill Act, which cuts nearly $1 trillion to Medicaid and threatens the ability for hospitals to provide care to uninsured patients.

"Dr. Watson, I've been to Mile Square [Health Center]. The people who come in there, some of them are covered by Medicaid, and now there's talk about taking $1 trillion out of Medicaid. What is that going to do?" Durbin asked.

Mr. Watson explained that he anticipates a drastic impact on his patient population. According to Mr. Watsom, more than 60 percent of their adult patients are covered by Medicaid, and if those patients become uninsured under the Republicans' Medicaid cuts, the cost of health care would go up as these uninsured patients would be more likely to seek treatment in emergency rooms only after their medical condition has worsened.

Durbin concluded by underscoring that eliminating health care coverage for millions of Americans leads to a sicker population and severe harms to hospitals' ability to provide care to patients. Durbin invoked his personal experience as an uninsured father desperate to find treatment for his newborn daughter with a serious heart condition.

"How could this be good for the country, for more and more people to be uninsured? Have you ever been uninsured with a sick baby? Yes [Durbin raises his own hand]. You will never forget it as long as you live. And we're going to do this to millions of people now?" Durbin concluded his questioning.

Video of Durbin's questions in Committee is available here.

Audio of Durbin's questions in Committee is available here.

Footage of Durbin's questions in Committee is available here for TV Stations.

-30-

  • Print
  • Email
  • Share
  • Post
U.S. Senate Committee on Judiciary published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 20:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]